GlycoMimetics, Inc. - Common Stock (GLYC)

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305 thousand shares in the company.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to advance its oncology pipeline.

Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.

It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!

Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!

GLYC stock results show that GlycoMimetics missed analyst estimates for earnings per share the first quarter of 2024.